{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:06:57Z","timestamp":1759565217791},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/wco.0b013e32832d9dc4","type":"journal-article","created":{"date-parts":[[2009,7,6]],"date-time":"2009-07-06T07:32:10Z","timestamp":1246865530000},"page":"394-399","source":"Crossref","is-referenced-by-count":14,"title":["Drug-induced dyskinesias"],"prefix":"10.1097","volume":"22","author":[{"given":"Philippe","family":"Damier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210206","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"R2-10-20210206","first-page":"133","article-title":"Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications","volume":"54","author":"Glazer","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"R3-10-20210206","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-10-20210206","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group.","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"R5-10-20210206","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","article-title":"The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study","volume":"18","author":"Bracco","year":"2004","journal-title":"CNS Drugs"},{"key":"R6-10-20210206","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"key":"R7-10-20210206","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"R8-10-20210206","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/WNL.0b013e318198e177","article-title":"When and how should treatment be started in Parkinson disease?","volume":"72","author":"Lang","year":"2009","journal-title":"Neurology"},{"key":"R9-10-20210206","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","article-title":"Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD","volume":"71","author":"Katzenschlager","year":"2008","journal-title":"Neurology"},{"key":"R10-10-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.63.2.205","article-title":"Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990","volume":"63","author":"Van Gerpen","year":"2006","journal-title":"Arch Neurol"},{"key":"R11-10-20210206","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","article-title":"Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study","volume":"123","author":"Schrag","year":"2000","journal-title":"Brain"},{"key":"R12-10-20210206","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov Disord"},{"key":"R13-10-20210206","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archneur.62.4.601","article-title":"Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study","volume":"62","author":"Zappia","year":"2005","journal-title":"Arch Neurol"},{"key":"R14-10-20210206","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","article-title":"Effect of pulsatile administration of levodopa on dyskinesia induction in drug-na\u00efve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure","volume":"18","author":"Smith","year":"2003","journal-title":"Mov Disord"},{"key":"R15-10-20210206","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001756-200403010-00035","article-title":"Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease","volume":"15","author":"Paill\u00e9","year":"2004","journal-title":"Neuroreport"},{"key":"R16-10-20210206","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1212\/WNL.41.2_Part_1.168","article-title":"Young-onset Parkinson's disease: a clinical review","volume":"41","author":"Golbe","year":"1991","journal-title":"Neurology"},{"key":"R17-10-20210206","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"key":"R18-10-20210206","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1212\/01.wnl.0000338460.89796.06","article-title":"Is the common LRRK2 G2019S mutation related to dyskinesias in North African Parkinson disease?","volume":"71","author":"Lesage","year":"2008","journal-title":"Neurology"},{"key":"R19-10-20210206","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Pais\u00e1n-Ru\u00edz","year":"2004","journal-title":"Neuron"},{"key":"R20-10-20210206","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMc055540","article-title":"LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs","volume":"354","author":"Lesage","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-10-20210206","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000074637","article-title":"Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease","volume":"48","author":"Watanabe","year":"2003","journal-title":"Neuropsychobiology"},{"key":"R22-10-20210206","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.WNL.0000068009.32067.A1","article-title":"L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism","volume":"60","author":"Kaiser","year":"2003","journal-title":"Neurology"},{"key":"R23-10-20210206","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1212\/WNL.53.7.1425","article-title":"Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD","volume":"53","author":"Oliveri","year":"1999","journal-title":"Neurology"},{"key":"R24-10-20210206","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/mds.20785","article-title":"Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease","volume":"21","author":"Strong","year":"2006","journal-title":"Mov Disord"},{"key":"R25-10-20210206","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jnnp.2008.154294","article-title":"BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease","volume":"80","author":"Foltynie","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R26-10-20210206","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"R27-10-20210206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-7091-6842-4_6","article-title":"Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia","volume":"50","author":"Calne","year":"1997","journal-title":"J Neural Transm Suppl"},{"key":"R28-10-20210206","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1212\/WNL.49.3.717","article-title":"In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias","volume":"49","author":"Turjanski","year":"1997","journal-title":"Neurology"},{"key":"R29-10-20210206","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10526","article-title":"Endogenous dopamine release after pharmacological challenges in Parkinson's disease","volume":"53","author":"Piccini","year":"2003","journal-title":"Ann Neurol"},{"key":"R30-10-20210206","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.46.5.1430","article-title":"Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET","volume":"46","author":"Tedroff","year":"1996","journal-title":"Neurology"},{"key":"R31-10-20210206","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.65","article-title":"Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover","volume":"49","author":"de la Fuente-Fern\u00e1ndez","year":"2001","journal-title":"Ann Neurol"},{"key":"R32-10-20210206","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"R33-10-20210206","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1212\/01.wnl.0000338631.73211.56","article-title":"PET demonstrates reduced dopamine transporter expression in PD with dyskinesias","volume":"72","author":"Troiano","year":"2009","journal-title":"Neurology"},{"key":"R34-10-20210206","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1523\/JNEUROSCI.12-11-04224.1992","article-title":"Long-term depression in the striatum: physiological and pharmacological characterization","volume":"12","author":"Calabresi","year":"1992","journal-title":"J Neurosci"},{"key":"R35-10-20210206","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.0953-816x.2001.01485.x","article-title":"Dopaminergic control of synaptic plasticity in the dorsal striatum","volume":"13","author":"Centonze","year":"2001","journal-title":"Eur J Neurosci"},{"key":"R36-10-20210206","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat Neurosci"},{"key":"R37-10-20210206","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/brain\/awl031","article-title":"Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias","volume":"129","author":"Morgante","year":"2006","journal-title":"Brain"},{"key":"R38-10-20210206","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-2236(03)00038-9","article-title":"Presymptomatic compensation in Parkinson's disease is not dopamine-mediated","volume":"26","author":"Bezard","year":"2003","journal-title":"Trends Neurosci"},{"key":"R39-10-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.09.013","article-title":"Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?","volume":"87","author":"Nadjar","year":"2009","journal-title":"Prog Neurobiol"},{"key":"R40-10-20210206","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R41-10-20210206","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1176\/ajp.147.9.1156","article-title":"Factors in the development of severe forms of tardive dyskinesia","volume":"147","author":"Yassa","year":"1990","journal-title":"Am J Psychiatry"},{"key":"R42-10-20210206","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-200017050-00004","article-title":"Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations","volume":"17","author":"Caligiuri","year":"2000","journal-title":"Drugs Aging"},{"key":"R43-10-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(99)00021-3","article-title":"The treatment of tardive dyskinesia: a systematic review and meta-analysis","volume":"39","author":"Soares","year":"1999","journal-title":"Schizophr Res"},{"key":"R44-10-20210206","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(05)60203-6","article-title":"Pallidotomy for tardive dyskinesia","volume":"349","author":"Wang","year":"1997","journal-title":"Lancet"},{"key":"R45-10-20210206","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.WNL.0000149762.80932.55","article-title":"Treatment of severe tardive dystonia with pallidal deep brain stimulation","volume":"64","author":"Trottenberg","year":"2005","journal-title":"Neurology"},{"key":"R46-10-20210206","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archpsyc.64.2.170","article-title":"Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia","volume":"64","author":"Damier","year":"2007","journal-title":"Arch Gen Psychiatry"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0b013e32832d9dc4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T08:08:59Z","timestamp":1620979739000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-200908000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32832d9dc4","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}